NASDAQ:NITE - Nightstar Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$25.41MA: $25.41▼$25.4152-Week Range N/AVolume40 shsAverage Volume185,808 shsMarket Capitalization$852.25 millionP/E RatioN/ADividend YieldN/ABeta2.84 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NITE Previous Symbol CUSIPN/A CIK1711675 Webhttp://www.nightstartx.com/ Phone44-20-7062-2777Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-36,860,000.00 Net MarginsN/A Return on Equity-30.89% Return on Assets-27.65%Miscellaneous Employees47 Outstanding Shares33,540,000Market Cap$852.25 million Next Earnings DateN/A OptionableNot Optionable Receive NITE News and Ratings via Email Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions What is Nightstar Therapeutics' stock symbol? Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE." How were Nightstar Therapeutics' earnings last quarter? Nightstar Therapeutics PLC (NASDAQ:NITE) posted its earnings results on Tuesday, November, 13th. The company reported ($0.27) EPS for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.13. View Nightstar Therapeutics' Earnings History. What price target have analysts set for NITE? 9 brokerages have issued twelve-month target prices for Nightstar Therapeutics' shares. Their forecasts range from $25.18 to $26.00. On average, they anticipate Nightstar Therapeutics' stock price to reach $25.53 in the next year. View Analyst Price Targets for Nightstar Therapeutics. What is the consensus analysts' recommendation for Nightstar Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nightstar Therapeutics. What are Wall Street analysts saying about Nightstar Therapeutics stock? Here are some recent quotes from research analysts about Nightstar Therapeutics stock: 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (5/7/2019) 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $42/share price target on Nightstar Therapeutics. This morning, Spark (N) announced a definitive agreement to be acquired by Roche (RHHBY, NC) for $4.8 billion, or $114.50/share (a 122% premium). While we believe the primary driver of the acquisition was Spark’s hemophilia A program, we have observed a trend in late- stage gene therapy company acquisitions. Given that Nightstar is one of the furthest along with a Phase 3 trial reading out next year, we believe the company deserves a seat at the table for acquisition talks and interest from pharma." (2/26/2019) Has Nightstar Therapeutics been receiving favorable news coverage? Headlines about NITE stock have been trending somewhat negative this week, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nightstar Therapeutics earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Nightstar Therapeutics. Who are some of Nightstar Therapeutics' key competitors? Some companies that are related to Nightstar Therapeutics include Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT) and Coherus Biosciences (CHRS). What other stocks do shareholders of Nightstar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nightstar Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals (LGND), NVIDIA (NVDA), Oncomed Pharmaceuticals (OMED), Sorrento Therapeutics (SRNE), Funko (FNKO), Neurocrine Biosciences (NBIX) and Sangamo Therapeutics (SGMO). Who are Nightstar Therapeutics' key executives? Nightstar Therapeutics' management team includes the folowing people: Mr. David Fellows, CEO & Director (Age 62)Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)Brian Luque, Sr. Mang. of Investor RelationsMr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40) When did Nightstar Therapeutics IPO? (NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers. How big of a company is Nightstar Therapeutics? Nightstar Therapeutics has a market capitalization of $0.00. The company earns $-36,860,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Nightstar Therapeutics employs 47 workers across the globe.View Additional Information About Nightstar Therapeutics. What is Nightstar Therapeutics' official website? The official website for Nightstar Therapeutics is http://www.nightstartx.com/. How can I contact Nightstar Therapeutics? Nightstar Therapeutics' mailing address is 10 MIDFORD PLACE 2ND FLOOR, LONDON X0, W1T5BJ. The company can be reached via phone at 44-20-7062-2777 or via email at [email protected] MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 217 (Vote Outperform)Underperform Votes: 186 (Vote Underperform)Total Votes: 403MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Analyst Ratings Trading
